by Josh | Aug 24, 2023 | Neurology Live
A recently published prospective population-based prognostic study evaluating combinations of different plasma biomarkers showed that phosphorylated tau 217 (P-tau217) was the best marker to predict cognitive decline in patients with preclinical Alzheimer disease...
by Josh | Aug 24, 2023 | PRN Newswire
Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all secondary endpoints measuring cognitive and functional decline Donanemab...
Recent Comments